Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $1.65 million versus the consensus estimate of $3.44 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.